INOVIO PHARMACEUTICALS, INC. — Net Income by Fiscal Year
17 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/e9ae6c2a-3ff7-4cdc-ad94-def7467e999a/serie/net-income
| Fiscal year | Net Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $-85.0M | 2025-01-01 – 2025-12-31 | evidence 0001055726-26-000011 |
| FY 2024 | $-107.0M | 2024-01-01 – 2024-12-31 | evidence 0001055726-26-000011 |
| FY 2023 | $-135.0M | 2023-01-01 – 2023-12-31 | evidence 0001055726-26-000011 |
| FY 2022 | $-279.8M | 2022-01-01 – 2022-12-31 | evidence 0001055726-23-000010 |
| FY 2021 | $-303.7M | 2021-01-01 – 2021-12-31 | evidence 0001055726-22-000008 |
| FY 2020 | $-166.4M | 2020-01-01 – 2020-12-31 | evidence 0001055726-21-000018 |
| FY 2019 | $-119.4M | 2019-01-01 – 2019-12-31 | evidence 0001055726-20-000012 |
| FY 2018 | $-97.0M | 2018-01-01 – 2018-12-31 | evidence 0001055726-19-000012 |
| FY 2017 | $-88.2M | 2017-01-01 – 2017-12-31 | evidence 0001055726-18-000014 |
| FY 2016 | $-73.7M | 2016-01-01 – 2016-12-31 | evidence 0001055726-17-000013 |
| FY 2015 | $-29.2M | 2015-01-01 – 2015-12-31 | evidence 0001055726-16-000033 |
| FY 2014 | $-36.1M | 2014-01-01 – 2014-12-31 | evidence 0001055726-15-000003 |
| FY 2013 | $-66.0M | 2013-01-01 – 2013-12-31 | evidence 0001055726-14-000003 |
| FY 2012 | $-19.7M | 2012-01-01 – 2012-12-31 | evidence 0001445305-13-000665 |
| FY 2011 | $-15.3M | 2011-01-01 – 2011-12-31 | evidence 0001193125-12-117292 |
| FY 2010 | $-17.6M | 2010-01-01 – 2010-12-31 | evidence 0001193125-12-117292 |
| FY 2009 | $-24.4M | 2009-01-01 – 2009-12-31 | evidence 0001193125-12-117292 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
INOVIO PHARMACEUTICALS, INC. — all facts · Revenue · Operating Income